Abstract

THE OBSERVATIONAL STUDY ON CLINICAL SAFETY AND EFFICACY OF TICAGRELOR IN PATIENT WITH ACUTE CORONARY SYNDROME

Dr. M.S.S Mukharjee*, Dr. D Pooja, Dr. Hafsa Fatima, Dr. V. Anudeep,
Dr. Zainab Begum, Dr. A. Srinivasa Rao

ABSTRACT

Acute coronary syndrome is a condition occurs due to interruption of blood supply to the heart mainly due to formation of clot in the coronary arteries. It is a leading cause of cardiovascular death. DAPT is the standard of care for patients with ACS. Ticagrelor is a novel, reversible directly acting, oral antiplatelet drug given twice daily (90mg) for a period of 6 months to 1year to prevent reinfarction, cardiovascular death, stent thrombosis in patients with ACS. It is given along with low dose asprin(75mg/day). The present study is a single centered, prospective observational study conducted in pluse heart center kukatpally, for a period of 6months. Our study was conducted on 120 patients out of which 60% of patients were found to be males and 40% are females. most of the patients (34.16%) had dm along with htn as a risk factor. most of the patients (84.16%) were diagnosed with unstable angina and remaining with stent (10%) and nstemi (5.8%). among those all patients 53.3% had single vessel disease. patients rbc (82.5%), hb (76.66%), platelets (96.66%) were found to be normal during course of treatment. 68% of the patients had adr’s and among these bleeding 23.3% and sob 12.71% are seen in majority of patients. The adrs are statistically analysed by using p-value. Based on our study we conclude that ticagrelor is highly effective in preventing reinfarction, cardiovascular death and stent thrombosis. There is no case of reinfarction cardiovascular death and stent thrombosis during the course of therapy. It is reasonably safe with bleeding and sob seen in many patients and for only 3 patients the drug has been stopped due to intracranial bleeding for one patient and severe black spots for 2 patients were seen. For rest of patients the drug was continued for period of 6 months to 1 year.

Keywords: acute coronary syndrome, dual antiplatelet therapy, coronary atherosclerosis plaques, P2Y12ADP receptor, dyspnea.